135 related articles for article (PubMed ID: 30190276)
1. Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Greuter MJE; Coupé VMH; Canfell K
Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1450-1461. PubMed ID: 30190276
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
3. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
[TBL] [Abstract][Full Text] [Related]
4. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
[TBL] [Abstract][Full Text] [Related]
5. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
[TBL] [Abstract][Full Text] [Related]
6. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
[TBL] [Abstract][Full Text] [Related]
7. Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia.
Worthington J; Feletto E; Lew JB; Broun K; Durkin S; Wakefield M; Grogan P; Harper T; Canfell K
Public Health; 2020 Feb; 179():90-99. PubMed ID: 31760206
[TBL] [Abstract][Full Text] [Related]
8. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
[TBL] [Abstract][Full Text] [Related]
9. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
[TBL] [Abstract][Full Text] [Related]
10. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
Ee H; St John J
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
[TBL] [Abstract][Full Text] [Related]
11. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data.
Tran B; Keating CL; Ananda SS; Kosmider S; Jones I; Croxford M; Field KM; Carter RC; Gibbs P
Intern Med J; 2012 Jul; 42(7):794-800. PubMed ID: 21883782
[TBL] [Abstract][Full Text] [Related]
12. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
13. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
Kang YJ; Killen J; Caruana M; Simms K; Taylor N; Frayling IM; Snowsill T; Huxley N; Coupe VM; Hughes S; Freeman V; Boussioutas A; Trainer AH; Ward RL; Mitchell G; Macrae FA; Canfell K
Med J Aust; 2020 Feb; 212(2):72-81. PubMed ID: 31595523
[TBL] [Abstract][Full Text] [Related]
14. History, development and future of cancer screening in Australia.
Olver IN; Roder D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
[TBL] [Abstract][Full Text] [Related]
15. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.
Vijan S; Hwang EW; Hofer TP; Hayward RA
Am J Med; 2001 Dec; 111(8):593-601. PubMed ID: 11755501
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of an advance notification letter to increase colorectal cancer screening.
Cronin P; Goodall S; Lockett T; O'Keefe CM; Norman R; Church J
Int J Technol Assess Health Care; 2013 Jul; 29(3):261-8. PubMed ID: 23778152
[TBL] [Abstract][Full Text] [Related]
17. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
